Cloghessy Paula 4
4 · Kailera Therapeutics, Inc. · Filed Apr 20, 2026
Research Summary
AI-generated summary of this filing
Kailera (KLRA) Chief People Officer Paula Cloghessy Receives Award
What Happened
Paula Cloghessy, Kailera Therapeutics' Chief People Officer, received two derivative awards on April 16, 2026: 60,000 shares each (120,000 total) reported as grants at a $0.00 price. These are derivative securities (option awards/stock-based awards) rather than open-market purchases or sales; no cash was paid and no shares were sold.
Key Details
- Transaction date: April 16, 2026; Form 4 filed April 20, 2026 (timely filed).
- Award amounts: two grants of 60,000 each = 120,000 total. Reported price: $0.00 (derivative).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnote F1 (time-based vesting): 25% vests on April 16, 2027, then the remainder vests in 36 substantially equal monthly installments, subject to continued service.
- Footnote F2 (performance vesting): a separate award vests in full if (i) the average Nasdaq closing price over any 30 consecutive calendar days between Oct 16, 2026 and Apr 16, 2030 reaches $40, or (ii) a change-in-control during that period has a stock price of at least $40, each subject to continued service.
Context
These were grant awards (A = Award/Grant), not sales or purchases; they do not represent immediate market buying/selling. One grant is time-based and the other is performance-based, so vesting (and any eventual ownership) depends on continued employment and, for the performance award, hitting a $40 stock-price trigger within the measurement window.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-04-16+60,000→ 60,000 totalExercise: $16.00Exp: 2036-04-16→ Common Stock (60,000 underlying) - Award
Stock Option (right to buy)
[F2]2026-04-16+60,000→ 60,000 totalExercise: $16.00Exp: 2036-04-16→ Common Stock (60,000 underlying)
Footnotes (2)
- [F1]The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
- [F2]The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.